Latest Articles
A combination of drugs shows efficacy against endometrial - Hospital Universitari Vall d'Hebron
A combination of drugs shows efficacy against endometrial Hospital Universitari Vall d'Hebron
Published: Sept. 18, 2026, 3:47 p.m.
A combination of drugs shows efficacy against endometrial - Vall d'Hebron Barcelona Hospital Campus
A combination of drugs shows efficacy against endometrial Vall d'Hebron Barcelona Hospital Campus
Published: Sept. 18, 2026, 9:47 a.m.
Add-Back Therapy: Balancing Efficacy and Safety in Endometriosis - contemporaryobgyn.net
Add-Back Therapy: Balancing Efficacy and Safety in Endometriosis contemporaryobgyn.net
Published: Sept. 2, 2026, 12:05 p.m.
Add-Back Therapy: Balancing Efficacy and Safety in Endometriosis - Contemporary OB/GYN
Add-Back Therapy: Balancing Efficacy and Safety in Endometriosis Contemporary OB/GYN
Published: Sept. 2, 2026, 12:05 p.m.
Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer - OncLive
Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer OncLive
Published: Aug. 12, 2026, 3:24 a.m.
BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - BioPharm International
BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer BioPharm International
Published: April 15, 2026, 10:02 p.m.
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial - BioSpace
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial BioSpace
Published: April 13, 2026, 5:57 p.m.
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9:01 p.m.
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer - OncLive
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer OncLive
Published: April 12, 2026, 6:25 p.m.
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive
Published: April 12, 2026, 2:35 p.m.
Link copied to clipboard!